Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation.

Lauver DA, Driscoll EM, Lucchesi BR.

Pharmacology. 2008;82(1):67-73. doi: 10.1159/000132085. Epub 2008 May 14.

PMID:
18477858
2.

Effect of sodium/hydrogen exchange inhibition on myocardial infarct size after coronary artery thrombosis and thrombolysis.

Hennan JK, Driscoll EM, Barrett TD, Fischbach PS, Lucchesi BR.

Pharmacology. 2006;78(1):27-37. Epub 2006 Apr 3.

PMID:
16899991
3.

Microvascular permeabilization and cardiomyocyte injury provoked by myocardial contrast echocardiography in a canine model.

Miller DL, Driscoll EM, Dou C, Armstrong WF, Lucchesi BR.

J Am Coll Cardiol. 2006 Apr 4;47(7):1464-8. Epub 2006 Mar 15.

4.

Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796.

Hennan JK, Willens DE, Driscoll EM Jr, Hong TT, Giboulot T, Lucchesi BR.

J Cardiovasc Pharmacol. 2003 Jul;42(1):71-7.

PMID:
12827029
6.

Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.

Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, Lucchesi BR.

Br J Pharmacol. 2002 Jul;136(6):927-37.

7.

Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury.

Hennan JK, Hong TT, Shergill AK, Driscoll EM, Cardin AD, Lucchesi BR.

J Pharmacol Exp Ther. 2002 Jun;301(3):1151-6.

PMID:
12023550
8.

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.

Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, Crofford LJ, Lucchesi BR.

Circulation. 2001 Aug 14;104(7):820-5.

PMID:
11502709
9.

Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence.

Barrett TD, Hennan JK, Fischbach PS, O'Neill BP, Driscoll EM Jr, Lucchesi BR.

Br J Pharmacol. 2001 Apr;132(7):1493-500.

10.

Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.

Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR.

J Pharmacol Exp Ther. 2000 Nov;295(2):492-9.

PMID:
11046080
11.
12.

Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation.

Friedrichs GS, Abreu JN, Driscoll EM Jr, Borlak J, Lucchesi BR.

J Cardiovasc Pharmacol. 1998 Jan;31(1):56-66.

PMID:
9456278
13.
14.
15.

Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury.

Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR.

Cardiovasc Res. 1995 May;29(5):629-36.

PMID:
7606750
16.
17.

Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion.

Black SC, Gralinski MR, McCormack JG, Driscoll EM, Lucchesi BR.

J Cardiovasc Pharmacol. 1994 Dec;24(6):921-8.

PMID:
7898075
19.

Inhibition of in vivo myocardial ischemic and reperfusion injury by a synthetic manganese-based superoxide dismutase mimetic.

Black SC, Schasteen CS, Weiss RH, Riley DP, Driscoll EM, Lucchesi BR.

J Pharmacol Exp Ther. 1994 Sep;270(3):1208-15.

PMID:
7932173
20.
21.

Inhibition of coronary artery reocclusion after thrombolysis with an RGD-containing peptide with no significant effect on bleeding time.

Tschopp JF, Driscoll EM, Mu DX, Black SC, Pierschbacher MD, Lucchesi BR.

Coron Artery Dis. 1993 Sep;4(9):809-17.

PMID:
8287215
22.

Inhibition of platelet-activating factor fails to limit ischemia and reperfusion-induced myocardial damage.

Black SC, Driscoll EM, Lucchesi BR.

J Cardiovasc Pharmacol. 1992 Dec;20(6):997-1005.

PMID:
1282605
23.

Antiarrhythmic and electrophysiologic actions of CK-3579 and sematilide in a conscious canine model of sudden coronary death.

Chi LG, Mu DX, Driscoll EM, Lucchesi BR.

J Cardiovasc Pharmacol. 1990 Aug;16(2):312-24.

PMID:
1697389
24.

Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction.

Lynch JJ Jr, Uprichard AC, Frye JW, Driscoll EM, Kitzen JM, Lucchesi BR.

J Cardiovasc Pharmacol. 1989 Oct;14(4):585-97.

PMID:
2478772
25.

Alinidine reduces the incidence of ischemic ventricular fibrillation in a conscious canine model, a protective effect antagonized by overdrive atrial pacing.

Uprichard AC, Chi LG, Lynch JJ, Driscoll EM, Frye JW, Lucchesi BR.

J Cardiovasc Pharmacol. 1989 Sep;14(3):475-82.

PMID:
2476629
26.

Superoxide dismutase conjugated to polyethylene glycol provides sustained protection against myocardial ischemia/reperfusion injury in canine heart.

Tamura Y, Chi LG, Driscoll EM Jr, Hoff PT, Freeman BA, Gallagher KP, Lucchesi BR.

Circ Res. 1988 Nov;63(5):944-59.

PMID:
3180357
27.

Cardiac electrophysiologic and hemodynamic activity of pimobendan (UD-CG 115 BS), a new inotropic agent.

Kitzen JM, Lynch JJ, Driscoll EM, Lucchesi BR.

J Pharmacol Exp Ther. 1988 Mar;244(3):929-39.

PMID:
3252039
28.
29.

Platelet-activating factor and the release of a platelet-derived coronary artery vasodilator substance in the canine.

Jackson CV, Schumacher WA, Kunkel SL, Driscoll EM, Lucchesi BR.

Circ Res. 1986 Feb;58(2):218-29.

PMID:
2868810
30.

The independent effects of oxygen radical scavengers on canine infarct size. Reduction by superoxide dismutase but not catalase.

Werns SW, Shea MJ, Driscoll EM, Cohen C, Abrams GD, Pitt B, Lucchesi BR.

Circ Res. 1985 Jun;56(6):895-8.

PMID:
2988815
31.

Effects of bepridil on regional and global myocardial ischemia/reperfusion-induced injury.

Jackson CV, Mitsos SE, Simpson PJ, Driscoll EM, Lucchesi BR.

Pharmacology. 1985;30(6):320-32.

PMID:
3874404
32.

Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog.

Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR.

Eur J Pharmacol. 1984 Oct 15;105(3-4):285-91.

33.

The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis.

Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR.

Am Heart J. 1984 Apr;107(4):629-37.

34.

Antiarrhythmic and cardiovascular actions of the new antibiotic agent pirlimycin adenylate.

Kopia GA, Driscoll EM, Yeung KF, Lucchesi BR.

Pharmacology. 1983;27(5):255-66.

PMID:
6606809
35.

The effect of diltiazem on coronary thrombosis in the conscious canine.

Shea MJ, Bush LR, Romson JL, Driscoll EM, Lucchesi BR.

Eur J Pharmacol. 1982 Jan 8;77(1):67-70.

Supplemental Content

Loading ...
Support Center